- An expert panel of the World Health Organization (WHO) will decide on the emergency use listing (EUL) authorization of Covaxin today.
- Covaxin is India's indigenously-developed COVID-19 vaccine, in collaboration with Ocugen Inc OCGN.
- Related: Ocugen-Partnered Covaxin's WHO Clearance Delayed Further Over Queries: Sources.
- According to SEC filing, Bharat Biotech International Limited will exclusively manufacture and supply Ocugen with its requirements of Covaxin clinical trial materials and manufacture & supply Covaxin drug product components and finished drug product after regulatory approval.
- Additionally, Ocugen amended the Co-Development and Commercialization Agreement with CanSino Biologics Inc and added Ocugen's OCU410 to the existing collaboration.
- OCU410 utilizes the nuclear receptor genes RAR-related orphan receptor A for dry age-related macular degeneration.
- CanSino will be responsible for the chemistry, manufacturing, and controls development and manufacture of clinical supplies of OCU410.
- CanSino will have an exclusive option to obtain a non-exclusive license to manufacture OCU410 commercially.
- CanSino will have an exclusive license to develop, manufacture, and commercialize OCU410 products in and for China, Hong Kong, Macau, and Taiwan.
- Ocugen will maintain exclusive development, manufacturing, and commercialization rights for OCU410 products outside the CanSino Territory.
- Price Action: OCGN stock is up 6.07% at $7.16 during the premarket session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
